Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus.
West Nile virus (WNV)-neutralizing intravenous immune globulins (IVIG) were fractionated into IgG subclasses, and the contribution of each subclass to in vitro neutralization of and in vivo protection against WNV was evaluated. The results indicate that IgG1 (i) is the main subclass induced following WNV infection of humans, (ii) contained nearly all the in vitro WNV neutralization capacity, and (iii) mediates effector functions in vivo that render it superior to other subclasses in protection against WNV. The importance of human IgG1 indicates that a candidate WNV vaccine should induce an immune response that includes WNV-specific IgG1.
Global Research and Development, Baxter BioScience, 1220 Vienna, Austria.
Yvonne
Y
Hofmeister
Christina B
CB
Planitzer
Maria R
MR
Farcet
Wolfgang
W
Teschner
H Arno
HA
Butterweck
Alfred
A
Weber
Georg W
GW
Holzer
Thomas R
TR
Kreil
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000145:classification* / Q000276:immunology / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D014901:West Nile Fever / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D053060:West Nile Virus Vaccines; D014902:West Nile virus / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D053060:West Nile Virus Vaccines